Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant
- Symbol
- TDACU
- Exchange
- NASDAQ
- Classification
- UNIT
Current Report · Items 8.01, 9.01 · 8-K
Translational Development Acquisition Corp.
TDACNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On July 6, 2026, Translational Development Acquisition Corp. issued a press release announcing that ProLogium Holding Inc. had filed a Registration Statement on Form F-4 with the U.S. Securities and Exchange Commission. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Press release in this filing
TDAC Announces ProLogium’s Filing of F-4 As Continuing Momentum Towards Merger →Company context
The Company is a blank check company incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business, industry, sector, or geographical location, and intends to focus on industries that complement its management team's background, and intends to capitalize on the ability of its management team to identify and acquire a business.
Current securities
Historical securities (1)
Recent company filings
- 10-Q filingAug 14, 2026
- SCHEDULE 13G - filed by METEORA CAPITAL, LLC regarding Translational Development Acquisition Corp.Aug 14, 2026
- SCHEDULE 13G/A - filed by Linden Capital L.P. regarding Translational Development Acquisition Corp.Aug 14, 2026
- 425 filingJul 27, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesJul 27, 2026
Registered securities in this filing
TRANSLATIONAL DEVELOPMENT ACQUISITION CORP. · 8-K · Filed 2026-07-08
Class A ordinary shares, $0.0001 par value per share
- Symbol
- TDAC
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
- Symbol
- TDACW
- Exchange
- NASDAQ
- Classification
- UNIT
- Status
- Current
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On July 6, 2026, Translational Development Acquisition
Corp. issued a press release announcing that ProLogium Holding Inc. had filed a Registration Statement on Form F-4 with the U.S. Securities
and Exchange Commission. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
Filed exhibits (1)
EX-99.1 2 tm2619975d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TDAC Announces ProLogium’s Filing of F-4 As Continuing Momentum Towards Merger NEW YORK, NY - July 6, 2026 - Translational Development Acquisition Company (NYSE: TDAC) ( “TDAC”) announced that ProLogium has filed their initial F-4 with the SEC driving the companies forward towards a successful execution of the de-SPAC transaction. This filing gives the SEC and investors at large a fuller view into the history of ProLogium and further supporting information into the merger transaction that was announced on May 27, 2026. Michael Hoffman, Chairman and CEO of TDAC, commented, “We continue to be tremendously excited to work with the ProLogium team on this transaction. We believe that this F-4 filing with the SEC will provide investors significant color into the company and the transaction and would be a tremendously helpful resource.” Please note that this filing is subject to SEC Review and may be revised. For further information please see ProLogium’s website at www.prologium.com and to access the filings please visit the SEC website at www.sec.gov. Forward-Looking Statements This communication contains forward-look…
Open exhibit ↗